T-cell lymphoma is a group of cancers that develop when T cells, a type of white blood cell that normally fights infections, become malignant and multiply uncontrollably. It falls under the broader category of non-Hodgkin lymphoma, but it’s uncommon. Most non-Hodgkin lymphomas arise from B cells, the other major type of immune cell. T-cell lymphomas account for roughly 10 to 15 percent of all non-Hodgkin lymphoma cases and tend to be more aggressive and harder to treat than their B-cell counterparts.
How T-Cell Lymphoma Develops
T cells are part of your adaptive immune system. They patrol your body, identify threats like viruses or bacteria, and coordinate the immune response. In T-cell lymphoma, something goes wrong inside these cells at a genetic level. Signaling pathways that tell cells when to grow, divide, and die become permanently switched on. One key pathway involves proteins that promote cell survival and resistance to the body’s normal self-destruct signals. As the disease progresses, these malignant T cells crowd out healthy immune cells, gradually weakening the body’s ability to fight infections.
What makes T-cell lymphoma particularly challenging is that the cancerous cells are diverse. Even within a single tumor, researchers using advanced genetic analysis have found that malignant T cells can carry different transcriptional signatures, meaning not all the cancer cells behave the same way. This internal diversity helps explain why these cancers can be difficult to treat with a single approach.
Major Types of T-Cell Lymphoma
T-cell lymphomas are not one disease. They’re a collection of subtypes that differ in where they appear, how fast they grow, and how they’re treated. The two broadest categories are peripheral T-cell lymphomas (PTCLs) and cutaneous T-cell lymphomas (CTCLs).
Peripheral T-Cell Lymphoma
PTCL refers to cancers of mature T cells that typically show up in lymph nodes, blood, bone marrow, or internal organs. These are usually aggressive. The most common subtypes include:
- PTCL-NOS (not otherwise specified): The most common subtype, essentially a catch-all for cases that don’t fit neatly into other categories.
- Anaplastic large cell lymphoma (ALCL): Comes in two forms based on whether the cancer cells produce a protein called ALK. ALK-positive ALCL tends to respond much better to treatment.
- Angioimmunoblastic T-cell lymphoma (AITL): Affects lymph nodes and often causes widespread symptoms like fever, rash, and enlarged lymph nodes throughout the body.
- Adult T-cell leukemia/lymphoma: Linked to a virus called HTLV-1 and more common in certain geographic regions.
Cutaneous T-Cell Lymphoma
CTCL starts in the skin. The two most recognized forms are mycosis fungoides, which typically begins as flat, scaly patches that can be mistaken for eczema or psoriasis, and Sézary syndrome, a more aggressive form where malignant T cells circulate in the bloodstream alongside skin involvement. CTCL often progresses slowly, sometimes over years or even decades, which sets it apart from most peripheral T-cell lymphomas.
Less common types include extranodal NK/T-cell lymphoma (which often starts in the nasal area), hepatosplenic T-cell lymphoma (affecting the liver and spleen), and enteropathy-associated T-cell lymphoma (linked to celiac disease and developing in the intestines).
Symptoms to Recognize
Symptoms depend heavily on the subtype and where the lymphoma develops. For peripheral T-cell lymphomas, common signs include swollen lymph nodes (often painless), persistent fatigue, unexplained weight loss, drenching night sweats, unexplained fevers, belly pain or swelling from an enlarged spleen, and skin rash. The combination of fever, night sweats, and weight loss is sometimes called “B symptoms” and generally signals more advanced disease.
Cutaneous T-cell lymphoma looks different. It typically starts on the skin as patches, plaques, or reddened areas that may itch. Early-stage mycosis fungoides can look so much like common skin conditions that it sometimes takes years to get a correct diagnosis. In more advanced stages, the skin lesions can thicken into raised tumors or spread to cover large areas of the body.
How It’s Diagnosed
Diagnosing T-cell lymphoma requires a tissue biopsy, usually from an affected lymph node or skin lesion. Pathologists examine the tissue under a microscope and run specialized tests to identify the type of cells involved. T-cell lymphomas express certain proteins on their surface that help confirm the diagnosis and determine the subtype.
For example, anaplastic large cell lymphoma is defined by strong expression of a protein called CD30 on the cancer cell surface. Whether the cells also produce the ALK protein matters significantly for prognosis and treatment decisions. ALK-positive cases result from a specific chromosomal rearrangement where two genes that shouldn’t be connected get fused together, creating an abnormal protein that drives cancer growth. Genetic testing for these rearrangements is now a standard part of the diagnostic workup.
Additional imaging, typically PET-CT scans, along with blood work and sometimes bone marrow biopsy, help determine how far the lymphoma has spread.
Treatment Approaches
Treatment depends on the subtype, stage, and the patient’s overall health. For aggressive peripheral T-cell lymphomas, the standard first-line treatment is combination chemotherapy. The most common regimen is CHOP (a four-drug combination), sometimes with a fifth drug, etoposide, added for patients 60 or younger, which has been shown to improve the rate of complete remission in that age group.
The challenge is that outcomes with standard chemotherapy remain significantly worse than for aggressive B-cell lymphomas treated with the same regimen. Five-year survival for PTCL patients treated with CHOP-based chemotherapy hovers around 20 to 30 percent in registry studies, which has driven the search for better options.
For CD30-positive subtypes, a targeted therapy called brentuximab vedotin has shown promising results. This drug works as an antibody-drug conjugate: it latches onto CD30 on the cancer cell surface and delivers a toxic payload directly inside. Studies have shown higher overall response rates with this approach compared to standard therapy for cutaneous T-cell lymphoma, and it’s now incorporated into frontline treatment for certain subtypes.
Cutaneous T-cell lymphoma that’s caught early is often managed with skin-directed therapies, including topical medications, phototherapy (controlled UV light exposure), and localized radiation. These approaches can control the disease for years. Systemic treatment is reserved for more advanced or refractory cases.
Stem Cell Transplant
For patients whose lymphoma comes back after initial treatment or doesn’t respond to it, stem cell transplant may be considered. An autologous transplant (using the patient’s own stem cells) is sometimes used to consolidate a good first response in high-risk patients. Allogeneic transplant (using a donor’s stem cells) is increasingly recognized as a potentially curative option for relapsed or refractory peripheral T-cell lymphoma. The European Society for Blood and Marrow Transplantation now recommends allogeneic transplant as standard of care for eligible patients with relapsed or refractory disease, because donor immune cells can produce a sustained anti-lymphoma effect that the patient’s own immune system cannot.
Survival Rates by Subtype
Survival varies dramatically depending on the specific type of T-cell lymphoma. Based on data from patients diagnosed between 2010 and 2019, the five-year survival rates break down roughly as follows:
- ALK-positive anaplastic large cell lymphoma: About 80 percent, the best prognosis among T-cell lymphomas.
- ALK-negative anaplastic large cell lymphoma: About 45 percent.
- Peripheral T-cell lymphoma overall: About 35 percent.
- PTCL-NOS: About 30 percent.
- Angioimmunoblastic T-cell lymphoma: About 30 percent.
These numbers represent averages across all stages and patient ages. Individual outcomes can differ considerably based on stage at diagnosis, age, response to initial treatment, and which specific therapies are available. Early-stage cutaneous T-cell lymphomas like mycosis fungoides, which aren’t captured in these statistics, often have a much more favorable outlook, with many patients living decades after diagnosis when the disease stays confined to the skin.